Suppr超能文献

皮质类固醇对急性呼吸窘迫综合征生理死腔分数的潜在影响。

Potential effects of corticosteroids on physiological dead-space fraction in acute respiratory distress syndrome.

机构信息

Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain.

出版信息

Respir Care. 2012 Mar;57(3):377-83. doi: 10.4187/respcare.01301. Epub 2011 Oct 12.

Abstract

BACKGROUND

Increased dead-space fraction is common in patients with persistent acute respiratory distress syndrome (ARDS). We evaluated the changes in the oxygenation and dead-space fraction in patients with persistent ARDS after corticosteroid therapy.

METHODS

This was a non-randomized non-placebo, controlled observational study including 19 patients with persistent ARDS treated with corticosteroids. We measured P(aO(2))/F(IO(2)) and dead-space fraction at days 0, 4, and 7 after corticosteroids treatment (methylprednisolone) initiation. Patients were classified in intermediate group when corticosteroids were initiated between days 8-14 after ARDS onset, and in late group when initiated after 14 days.

RESULTS

Mean time from the diagnosis of the ARDS to methylprednisolone treatment was 11 ± 2 days in the intermediate group (10 patients) and 21 ± 8 days in the late group (9 patients). When comparing days 0, 4, and 7 after methylprednisolone treatment, we found an increase in the P(aO(2))/F(IO(2)) (145 ± 64 mm Hg, 190 ± 68 mm Hg, and 226 ± 84 mm Hg, respectively, P < .001) and a decrease in the physiological dead-space fraction (0.66 ± 0.10, 0.58 ± 0.12, and 0.53 ± 0.11, respectively, P < .001). No differences were found between the intermediate and late groups.

CONCLUSIONS

In patients with persistent ARDS, the increase in oxygenation was accompanied by a decrease in the dead-space fraction after a few days of corticosteroid treatment. To confirm potential benefit of corticosteroids on physiological parameters and mortality will require a powered randomized placebo controlled trial.

摘要

背景

持续性急性呼吸窘迫综合征(ARDS)患者的死腔分数增加很常见。我们评估了皮质类固醇治疗后持续性 ARDS 患者的氧合和死腔分数的变化。

方法

这是一项非随机、非安慰剂对照的观察性研究,包括 19 例接受皮质类固醇治疗的持续性 ARDS 患者。我们在皮质类固醇(甲泼尼龙)治疗开始后第 0、4 和 7 天测量了肺泡氧分压(P(aO(2)))与吸入氧分数(F(IO(2)))比和死腔分数。皮质类固醇治疗开始于 ARDS 发病后第 8-14 天的患者归入中间组,开始于第 14 天后的患者归入晚期组。

结果

中间组(10 例)皮质类固醇治疗开始至 ARDS 诊断的平均时间为 11 ± 2 天,晚期组(9 例)为 21 ± 8 天。比较皮质类固醇治疗后第 0、4 和 7 天,我们发现 P(aO(2)))与吸入氧分数(F(IO(2)))比(分别为 145 ± 64 mm Hg、190 ± 68 mm Hg 和 226 ± 84 mm Hg,P <.001)升高,生理性死腔分数(分别为 0.66 ± 0.10、0.58 ± 0.12 和 0.53 ± 0.11,P <.001)降低。中间组和晚期组之间无差异。

结论

在持续性 ARDS 患者中,皮质类固醇治疗数天后,氧合增加的同时死腔分数降低。要确定皮质类固醇对生理参数和死亡率的潜在益处,需要进行有统计学效力的随机安慰剂对照试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验